NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and […]
-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies-– CTX001 has received orphan drug designation from the U.S. [...]